Biogen Buys Apellis for $5.6B to Expand Kidney Drugs
Bloomberg's Michelle Davis joins Dani Burger on "Bloomberg Deals." Biogen has agreed to acquire Apellis Pharmaceuticals for $5.6 billion, expanding its treatments in immunology and rare diseases in one of the company's largest-ever acquisitions.
_1373421_640x360_2494726723793-640x360.webp&w=3840&q=75)

_1373410_640x360_2494720579886-640x360.webp&w=3840&q=75)

_1373365_640x360_2494712899824-640x360.webp&w=3840&q=75)

_1373337_640x360_2494710851642-640x360.webp&w=3840&q=75)
_1373328_640x360_2494706243980-640x360.webp&w=3840&q=75)